Autoimmune diseases and longevity research are deeply connected. Chronic inflammation, a key driver of autoimmune conditions, also accelerates biological aging, leading to cellular damage and long-term health decline. As biotech advances in cell therapy and immunomodulation, the intersection of autoimmune treatment and longevity science is becoming a critical focus for researchers and investors.
At the Autoimmune and Cell Therapy Symposium in San Diego on March 26, 2025, Artem Trotsyuk, partner at LongeVC, will join the investor panel "Funding Biotech in Uncertain Times." Hosted by Aquillius and Aquillius Ventures, the event will bring together biotech leaders, researchers, and investors to explore innovation in autoimmune and cell therapy.
The discussion will cover the evolving biotech investment landscape, the challenges of scaling new therapeutics, and the growing intersection between autoimmune research and longevity. The symposium will also feature a startup showcase, highlighting emerging companies developing solutions in this space.
If you’re in San Diego and want to connect in person, reach out to Artem or email hq@longevc.com to set up a meeting.
For more details, visit the event website.
At the Autoimmune and Cell Therapy Symposium in San Diego on March 26, 2025, Artem Trotsyuk, partner at LongeVC, will join the investor panel "Funding Biotech in Uncertain Times." Hosted by Aquillius and Aquillius Ventures, the event will bring together biotech leaders, researchers, and investors to explore innovation in autoimmune and cell therapy.
The discussion will cover the evolving biotech investment landscape, the challenges of scaling new therapeutics, and the growing intersection between autoimmune research and longevity. The symposium will also feature a startup showcase, highlighting emerging companies developing solutions in this space.
If you’re in San Diego and want to connect in person, reach out to Artem or email hq@longevc.com to set up a meeting.
For more details, visit the event website.